Federico Pollano about the Key Growth Drivers for CDMOs

How will the CDMO market grow over the next few years and what will be the key growth drivers? Federico Pollano, our Senior Vice President Business Development and Client Program Management, recently provided some insights into this exciting topic and the vital role played by advanced therapies.

The international CDMO sector is experiencing substantial growth, driven by rising demand across therapeutic areas such as oncology, autoimmune, neurological diseases, infections, and rare diseases. According to Frost & Sullivan, the Bio-CDMO market is projected to grow at a compound annual growth rate of 14.3% from 2023 to 2029. Specifically, protein and antibody therapeutics are expected to grow at over 8%, while advanced therapies, including cell and gene therapies, are anticipated to surge by approximately 33%. 

This growth is significantly fueled by a robust pipeline of next-generation therapeutics developed by innovative companies that do not possess their own production capabilities. These companies represent 70% of the R&D pipeline and increasingly depend on CDMOs for manufacturing support. Additionally, Big Pharma is increasingly outsourcing late-stage product candidates and market products to CDMOs, recognizing the value of external expertise. 

At Rentschler Biopharma, we support clients from Phase I development through to commercial production for the market. Our recent contribution to successful FDA approvals—contributing to four out of 17 biopharmaceuticals approved in 2023—showcases our ability to deliver integrated services, including world-class consulting, regulatory support, process development, technology transfer, and cGMP manufacturing. 

We are also deeply engaged in the field of advanced therapies, which demands specialized expertise and cutting-edge technology platforms. Our objective is to assist clients in navigating the complex regulatory landscape and securing essential funding, thereby facilitating the advancement of innovative therapies. 

In summary, the expansion of therapeutic areas, the rise of advanced modalities, and the growing reliance on CDMOs by both innovative and established companies are key drivers of growth in the sector.